Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares of common stock in connectio
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerBusiness Wire
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
STOK
Earnings
- 3/25/24 - Beat
STOK
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- STOK's page on the SEC website